Jasper Therapeutics Inc. (JSPR)

$0.93 -0.01 (-0.61%)
Market Cap 26.21M
Revenue (ttm) 0.00
Net Income (ttm) -75.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 222,600
Avg Vol 443,748
Day's Range N/A - N/A
Shares Out 28.00M
Stochastic %K 47%
Beta 3.20
Analysts Sell
Price Target $7.70

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 549 1400
Address:
2200 Bridge Pkwy, Suite 102, Redwood City, United States
shehww
shehww Apr. 30 at 8:50 PM
$JSPR
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 10:08 PM
$MNTS $IPX $JSPR $CTRM BPBP
0 · Reply
Emergency123
Emergency123 Apr. 25 at 9:05 AM
$JSPR 🚀CNBX – Deep Value Biotech Flying Under the Radar 🚀 CNBX is one of those ultra-low market cap biotech plays that could move FAST when attention comes in. 💊 Cancer-Focused Pipeline CNBX is developing multiple cannabinoid-based cancer therapies, including treatments targeting colorectal, breast, prostate, and melanoma cancers. Their lead candidates like Cannabics SR and RCC-33 are aimed at massive global markets. () Got eyes on it?
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:53 PM
$JSPR 62%
0 · Reply
Bullshyte
Bullshyte Apr. 20 at 6:39 PM
$JSPR https://www.msn.com/en-us/money/markets/jasper-shares-surge-following-encouraging-early-asthma-trial-data/ar-AA1Rz7Hy?ocid=BingNewsVerp
1 · Reply
Bullshyte
Bullshyte Apr. 18 at 6:21 AM
$JSPR Extremely
0 · Reply
KOWALSK1
KOWALSK1 Apr. 17 at 9:39 PM
$JSPR 46% 💥 💥 💥
0 · Reply
Mario19860
Mario19860 Apr. 17 at 5:28 PM
$JSPR what this mean?
0 · Reply
shehww
shehww Apr. 16 at 3:32 PM
$JSPR next stop 1.45$ 😊
0 · Reply
shehww
shehww Apr. 16 at 1:15 PM
$JSPR ...🔥🔥🔥
0 · Reply
Latest News on JSPR
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 4:30 PM EDT - 4 weeks ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:50 PM EST - 2 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Feb 24, 2026, 4:30 PM EST - 2 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 4 months ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 8, 2026, 7:00 AM EST - 4 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Jan 7, 2026, 4:30 PM EST - 4 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:00 PM EST - 5 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 2, 2025, 7:00 AM EST - 5 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Dec 1, 2025, 4:30 PM EST - 5 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Nov 22, 2025, 11:49 PM EST - 5 months ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 17, 2025, 12:13 PM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 3:30 PM EST - 6 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:00 PM EST - 6 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 6 months ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 7, 2025, 9:52 AM EST - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Jasper Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Oct 10, 2025, 8:05 PM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 22, 2025, 1:05 PM EDT - 7 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 19, 2025, 12:07 AM EDT - 8 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 8 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 8 months ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 11, 2025, 12:18 PM EDT - 10 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 9, 2025, 8:00 AM EDT - 10 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 1:25 PM EDT - 10 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 10 months ago

Jasper Therapeutics Transcript: Study Update

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jul 7, 2025, 7:30 AM EDT - 10 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Transcript: Status Update

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 14, 2025, 10:00 AM EDT - 11 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 11 months ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

Jun 3, 2025, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 20, 2024, 12:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 2:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Jasper Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Jasper Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jasper Therapeutics Transcript: Status Update

May 20, 2024, 8:00 AM EDT - 2 years ago

Jasper Therapeutics Transcript: Status Update

Jasper Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 15, 2024, 3:35 PM EDT - 2 years ago

Jasper Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Jasper Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 11:00 AM EDT - 2 years ago

Jasper Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Jasper Therapeutics Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 28, 2024, 10:00 AM EDT - 2 years ago

Jasper Therapeutics Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Jasper Therapeutics Transcript: Investor Update

Jan 31, 2023, 8:30 AM EST - 3 years ago

Jasper Therapeutics Transcript: Investor Update

shehww
shehww Apr. 30 at 8:50 PM
$JSPR
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 10:08 PM
$MNTS $IPX $JSPR $CTRM BPBP
0 · Reply
Emergency123
Emergency123 Apr. 25 at 9:05 AM
$JSPR 🚀CNBX – Deep Value Biotech Flying Under the Radar 🚀 CNBX is one of those ultra-low market cap biotech plays that could move FAST when attention comes in. 💊 Cancer-Focused Pipeline CNBX is developing multiple cannabinoid-based cancer therapies, including treatments targeting colorectal, breast, prostate, and melanoma cancers. Their lead candidates like Cannabics SR and RCC-33 are aimed at massive global markets. () Got eyes on it?
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:53 PM
$JSPR 62%
0 · Reply
Bullshyte
Bullshyte Apr. 20 at 6:39 PM
$JSPR https://www.msn.com/en-us/money/markets/jasper-shares-surge-following-encouraging-early-asthma-trial-data/ar-AA1Rz7Hy?ocid=BingNewsVerp
1 · Reply
Bullshyte
Bullshyte Apr. 18 at 6:21 AM
$JSPR Extremely
0 · Reply
KOWALSK1
KOWALSK1 Apr. 17 at 9:39 PM
$JSPR 46% 💥 💥 💥
0 · Reply
Mario19860
Mario19860 Apr. 17 at 5:28 PM
$JSPR what this mean?
0 · Reply
shehww
shehww Apr. 16 at 3:32 PM
$JSPR next stop 1.45$ 😊
0 · Reply
shehww
shehww Apr. 16 at 1:15 PM
$JSPR ...🔥🔥🔥
0 · Reply
Mario19860
Mario19860 Apr. 16 at 12:19 PM
$JSPR whats happening?
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:09 AM
$JSPR
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:03 AM
$JSPR
0 · Reply
Bullshyte
Bullshyte Apr. 15 at 6:30 PM
$JSPR
0 · Reply
Chrissytina
Chrissytina Apr. 15 at 5:56 PM
$JSPR Whatever you do…just close above $1 everyday!
0 · Reply
Bullshyte
Bullshyte Apr. 14 at 12:08 PM
$JSPR Still time to get in at this insane price...
1 · Reply
KOWALSK1
KOWALSK1 Apr. 13 at 9:31 PM
$JSPR here we gooo boom
0 · Reply
Bullshyte
Bullshyte Apr. 13 at 5:12 PM
$JSPR
0 · Reply
shehww
shehww Apr. 13 at 2:16 PM
$JSPR
1 · Reply
LouKojak
LouKojak Apr. 13 at 1:04 AM
$JSPR $1.02 cash per share but quick ratio only 2.62. A lot of high cash biotechs have a quick ratio over 8. There's no cash for research. Looks like an offering is expected withinin the next 12 months.
0 · Reply
Chrissytina
Chrissytina Apr. 10 at 3:11 PM
$JSPR This needs some volume!
0 · Reply
Axeknight
Axeknight Apr. 9 at 5:33 PM
$JSPR
0 · Reply